Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Sarepta Therapeutics (NASDAQ: SRPT ) has been one roller coaster of a stock over the last year while waiting for the Food and Drug Administration to make up its mind about whether its Duchenne muscular dystrophy drug, eteplirsen, deserves an accelerated approval.
In November, Sarepta fell sharply after the biotech told investors that the FDA wasn't sure Sarepta had enough data to justify an accelerated approval. It appears the phase 3 failure of Prosensa (NASDAQ: RNA ) and GlaxoSmithKline's (NYSE: GSK ) Duchenne muscular dystrophy drug, drisapersen, influenced the FDA's decision.
In the video below, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss Sarepta's current predicament and give some advice on how investors should think about the long-term prospects of the company.